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The homeostatic systems regulating energy and glucose metabolism perform a complex balancing act of meeting short term requirements for increased energy whilst maintaining long term energy stores. Multiple signals are involved in this process, from the gastrointestinal tract, pancreas and adipose tissue, which in turn also modulate CNS pathways to control appetite and glucose metabolism. The effectiveness of bariatric surgery in treating both obesity and diabetes has highlighted the importance of gut hormones in metabolic control. A long list of signals released from enteroendocrine cells in the gastrointestinal tract act to regulate feeding, induce satiety and control blood glucose, among them cholecystokinin released from I cells, ghrelin from the gastric mucosa, peptide YY, oxyntomodulin and glucagon-like peptide 1 from the L cells. Recently, fibroblast growth factor 19 (FGF-19) and its rodent homolog, FGF-15, have been added to the catalog of gastrointestinal hormones regulating metabolism. FGF19 levels are reduced in individuals with metabolic syndrome, non-alcoholic fatty liver disease and FGF19 levels are restored to normal values in obese patients who undergo Roux-en-Y gastric bypass bariatric surgery [1, 2] . FGF-15 is released from enteroendocrine cells of the ileum in response to post-prandial secretion of bile acids and reduces weight and improves glucose tolerance in obese mice, effects that were believed to be mediated through peripheral effects, mostly on the liver [1] . However, recent papers by Marcelin, in the current edition of Molecular Metabolism [3] , Ryan et al. [4] and Morton et al. [5] [6] . The advantage of the clamp is that it is able to control insulin levels while maintaining euglycemia. This clamp can be used to study insulin action when insulin is raised as is done during a hyperinsulinemic clamp. However, the direct effects of insulin on the liver are potent and often override more subtle regulators such as a modulation of the autonomic nervous system that can also regulate hepatic glucose fluxes. Thus, the direct actions of insulin on the liver during a hyperinsulinemic clamp will in many settings mask the more subtle effects that are exerted via the CNS on the liver and it is therefore often not a good protocol to study the role of the CNS in controlling hepatic glucose fluxes. For that reason Rossetti et al. studied the effects of centrally infused hormones with the basal insulin clamp protocol where insulin is kept at low levels, an experimental protocol that turned out to be a more sensitive approach to studying the roles of central hormone signaling in regulating glucose fluxes and that has been used by several investigator [7] [8] [9] . During a basal clamp the direct effects of insulin on the liver are mostly absent (as insulin is low) and insulin concentrations are maintained constant and not raised [8] and therefore one can make the argument that what is assessed is not insulin action per se, but rather insulin independent effects on glucose fluxes, for example due to a change in autonomic input to the liver. Admittedly, most investigators, one of the authors included have described the effects of central infusions of hormones such as leptin and insulin on hepatic glucose fluxes during a basal insulin clamp, as an assessment of hepatic insulin action, which, based on above considerations, is not accurate [7] [8] [9] . It is quite possible that the basal clamp and the FSIGT study the same phenomenon of insulin independent regulation of glucose fluxes, with the clamp having the advantage that one avoids unphysiologic hyperglycemia and is able to control circulating insulin levels. What are the advantages of the FSIGT versus a clamp? The FSIGT does not require a somatostatin infusion which is used to control insulin secretion during a clamp. Since somatostatin receptors are expressed at many sites within the CNS it is possible that somatostatin may interfere with the central actions of hormones. A direct comparison of the basal clamp with the FSIGT as a method to characterize the effects of CNS control of glucose fluxes would be useful to test if both methods describe the same insulin independent phenomenon as further validation of these two methods to study CNS control of nutrient partitioning. [11] while these studies suggest that FGF-19 still is able to act via the CNS [3, 4] which positions FGF-19 as a promising therapeutic target for the treatment of obesity and diabetes. Thus, while these studies identify the CNS actions of the gut hormone FGF-19 as an important regulatory pathway in glucose homeostasis, they also may lead to a reappraisal of the methods used to study CNS control of glucose partitioning.
